Scientist I, NGS at Abata Therapeutics

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Gene TherapyIndustries

Requirements

BS/MS in molecular/cellular biology, biochemistry, or related field
5+ years relevant laboratory experience in an academic or biopharmaceutical setting
Extensive experience in NGS library preparation and instrumental operation
Molecular cloning (e.g., traditional, Golden Gate, Gibson, etc.)
Protein biochemistry and enzyme activity assays (Extraction, Western blot, etc.)
Experience in RNA/DNA processing, qPCR, and RT-PCR/ddPCR
Detail-oriented, well organized, and dependable record keeping
Highly motivated team member with excellent communication skills
Demonstrated problem-solving and troubleshooting skills
Experience in NGS data analysis is a plus

Responsibilities

Prepare and sequence a range of NGS library types to support discovery efforts
Develop and optimize custom NGS assays (short read and long read)
Maintain cell cultures and conduct cellular assays
Work independently and collaboratively with multi-disciplinary teams to solve complex problems
Maintain detailed records using ELN
Collaborate and communicate across a diverse research team to progress scientific goals
Support the creation and expansion of the company’s intellectual property
Help create an entrepreneurial and creative culture that will deliver transformational therapies to patients

Skills

NGS

library preparation

sequencing

molecular biology

cell culture

cellular assays

genomics

short read sequencing

long read sequencing

ELN

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free